-
1
-
-
0034040527
-
An update on satraplatin: The first orally available platinum anticancer drug
-
Kelland L.R. An update on satraplatin: The first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000, 9:1373-1382.
-
(2000)
Expert Opin Investig Drugs
, vol.9
, pp. 1373-1382
-
-
Kelland, L.R.1
-
2
-
-
0029121585
-
DNA-binding properties of novel cis- and trans- platinum-based anticancer agents in 2 human ovarian carcinoma cell lines
-
Mellish K.J., Barnard C.F., Murrer B.A., et al. DNA-binding properties of novel cis- and trans- platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 1995, 62:717-723.
-
(1995)
Int J Cancer
, vol.62
, pp. 717-723
-
-
Mellish, K.J.1
Barnard, C.F.2
Murrer, B.A.3
-
3
-
-
0036608548
-
JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumor cell lines with different sensitivities to cisplatin
-
Fokkema E., Groen H.J., Helder M.N., et al. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumor cell lines with different sensitivities to cisplatin. Biochem Pharmacol 2002, 63:1989-1996.
-
(2002)
Biochem Pharmacol
, vol.63
, pp. 1989-1996
-
-
Fokkema, E.1
Groen, H.J.2
Helder, M.N.3
-
4
-
-
0027253182
-
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): An orally active platinum drug
-
Kelland L.R., Abel G., McKeage M.J., et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): An orally active platinum drug. Cancer Res 1993, 53:2581-2586.
-
(1993)
Cancer Res
, vol.53
, pp. 2581-2586
-
-
Kelland, L.R.1
Abel, G.2
McKeage, M.J.3
-
5
-
-
0026665349
-
Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin
-
Twentyman P.R., Wright K.A., Mistry P., et al. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992, 52:5674-5680.
-
(1992)
Cancer Res
, vol.52
, pp. 5674-5680
-
-
Twentyman, P.R.1
Wright, K.A.2
Mistry, P.3
-
6
-
-
0029089517
-
A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration
-
McKeage M.J., Mistry P., Ward J., et al. A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995, 36:451-458.
-
(1995)
Cancer Chemother Pharmacol
, vol.36
, pp. 451-458
-
-
McKeage, M.J.1
Mistry, P.2
Ward, J.3
-
7
-
-
0030742993
-
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer
-
McKeage M.J., Raynaud F., Ward J., et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997, 15:2691-2700.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2691-2700
-
-
McKeage, M.J.1
Raynaud, F.2
Ward, J.3
-
9
-
-
0032423757
-
Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days
-
Sessa C., Minoia C., Ronchi A., et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998, 9:1315-1322.
-
(1998)
Ann Oncol
, vol.9
, pp. 1315-1322
-
-
Sessa, C.1
Minoia, C.2
Ronchi, A.3
-
10
-
-
34447536763
-
Preclinical antitumor activity of the oral platinum analog satraplatin
-
Wosikowski K., Lamphere L., Unteregger G., et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 2007, 60:589-600.
-
(2007)
Cancer Chemother Pharmacol
, vol.60
, pp. 589-600
-
-
Wosikowski, K.1
Lamphere, L.2
Unteregger, G.3
-
11
-
-
0031159653
-
Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation
-
Judson I., Cerny T., Epelbaum R., et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation. Ann Oncol 1997, 8:604-606.
-
(1997)
Ann Oncol
, vol.8
, pp. 604-606
-
-
Judson, I.1
Cerny, T.2
Epelbaum, R.3
-
12
-
-
0032791924
-
Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer
-
Fokkema E., Groen H.J., Bauer J., et al. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 1999, 17:3822-3827.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3822-3827
-
-
Fokkema, E.1
Groen, H.J.2
Bauer, J.3
-
13
-
-
0036169155
-
A phase II trial of JM-216 in cervical cancer: An NCIC CTG study
-
Trudeau M., Stuart G., Hirte H., et al. A phase II trial of JM-216 in cervical cancer: An NCIC CTG study. Gynecol Oncol 2002, 84:327-331.
-
(2002)
Gynecol Oncol
, vol.84
, pp. 327-331
-
-
Trudeau, M.1
Stuart, G.2
Hirte, H.3
-
14
-
-
8644219658
-
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily × 5 in hormone refractory prostate cancer (HRPC)
-
Latif T., Wood L., Connell C., et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily × 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005, 23:79-84.
-
(2005)
Invest New Drugs
, vol.23
, pp. 79-84
-
-
Latif, T.1
Wood, L.2
Connell, C.3
-
15
-
-
20944439837
-
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer
-
Sternberg C.N., Whelan P., Hetherington J., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005, 68:2-9.
-
(2005)
Oncology
, vol.68
, pp. 2-9
-
-
Sternberg, C.N.1
Whelan, P.2
Hetherington, J.3
-
16
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
-
(2004)
N Engl J Med
, vol.351
, pp. 1502-1512
-
-
Tannock, I.F.1
de Wit, R.2
Berry, W.R.3
-
17
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
-
(2004)
N Engl J Med
, vol.351
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
-
18
-
-
41549116526
-
Satraplatin, an oral platinum analog, is active and synergistic with paclitaxel and docetaxel in prostate carcinoma models
-
Lamphere L., Obermayr F., Caligiuri M., et al. Satraplatin, an oral platinum analog, is active and synergistic with paclitaxel and docetaxel in prostate carcinoma models. J Clin Oncol [Meeting Abstract] 2006, 24:14620.
-
(2006)
J Clin Oncol [Meeting Abstract]
, vol.24
, pp. 14620
-
-
Lamphere, L.1
Obermayr, F.2
Caligiuri, M.3
-
19
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
20
-
-
71849107626
-
Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small-cell lung cancer (NSCLC) treatment: Final results
-
Thompson D.S., Spigel D.R., Hainsworth J.D., et al. Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small-cell lung cancer (NSCLC) treatment: Final results. J Clin Oncol [Meeting Abstracts] 2008, 26:19023.
-
(2008)
J Clin Oncol [Meeting Abstracts]
, vol.26
, pp. 19023
-
-
Thompson, D.S.1
Spigel, D.R.2
Hainsworth, J.D.3
-
21
-
-
73949098659
-
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial
-
Sternberg C.N., Petrylak D.P., Sartor O., et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 2009, 27:5431-5438.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5431-5438
-
-
Sternberg, C.N.1
Petrylak, D.P.2
Sartor, O.3
|